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A b s t r a c t
Introduction: Constant technological progress in the field of carotid stenting translates into improved short- and long-term 
results of endovascular treatment. The introduction of a new generation, self-expanding, open-cell stent has provided a new treat-
ment option in endovascular management of carotid stenosis.
Aim: To evaluate 30-day and 1-year clinical outcomes of non-consecutive patients with high risk of carotid endarterectomy, who 
underwent 5F cylinder-tapered MER™ open-cell carotid stent implantation. 
Material and methods: It was a single-arm, prospective study conducted in four experienced catheterisation centres. The use of 
embolic protection devices was mandatory. The primary endpoint was stroke in 30-day follow-up. The secondary endpoints were 30-
day and 1-year cumulative incidence of death, stroke and myocardial infarction, 1-year target vessel revascularisation, procedural 
success (residual stenosis ≤ 30%), restenosis rate (%DS ≥ 50%), and Serious Adverse Device Effect (SADE) rate in 1-year follow-up. 
Results: In total 100 patients were recruited for the study, with the majority being males (n = 61). The mean age was 68.3 ±8.2 
years, and most of the patients were asymptomatic (n = 56). In 55 (55%) patients direct stenting was performed, with the use of 
proximal protection devices in 19 (19%) patients. Mean internal carotid artery/common carotid artery stenosis before and after 
stent implantation was 81.98 ±9.15% and 12.52 ±8.70%, respectively (p < 0.001). Procedural success was achieved in all cases. One 
ischaemic stroke was observed at 30 days (1%, primary endpoint). At 1-year follow-up two myocardial infarctions and three deaths 
occurred with no additional stroke. 
Conclusions: The OCEANUS study indicated the safety and efficacy of the MER™ stent during 30-day and 1-year follow-up in 
both symptomatic and asymptomatic patients. The majority of patients were event-free. However, larger cohort studies are needed 
to evaluate MER™ stents in detail.
Key words: carotid artery stenosis, carotid artery stenting, self-expanding carotid stents, open-cell stent.
S u m m a r y
The OCEANUS study confirmed the safety and efficacy of the MER™ stent during 30-day and 1-year follow-up in both 
symptomatic and asymptomatic patients. The majority of patients were event-free. However, larger cohort studies are needed 
to evaluate MER™ stents in detail.
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Introduction
Carotid artery stenting (CAS) with distal and proximal 
cerebral protection devices is an established method of 
invasive treatment of atherosclerotic stenosis of carotid 
arteries. The most important randomised controlled tri-
al, the CREST trial, demonstrated similar immediate and 
long-term outcomes of CAS and carotid endarterectomy 
(CEA) [1, 2]. 
Conditions that determine a  good result of CAS in-
clude operator experience, as well as the proper selection 
of stents and protection devices based on the patient’s 
clinical condition, atherosclerotic plaque morphology, 
and the anatomy of the carotid artery [3–5]. 
Two types of self-expanding stents are used in con-
ventional CAS: open-cell and closed-cell.  However, bal-
loon-expandable metal stents are preferred for the treat-
ment of ostial common carotid artery (CCA) stenosis and 
brachiocephalic trunk stenosis. Another option is the use 
of so-called mesh-covered stents, which may be a solution 
to eliminate late embolic complications after CAS [6, 7]. 
However, these stents still require further long-term eval-
uation. The continuous progress and reduction of peripro-
cedural complications are possible thanks to the use of 
new types of protection devices and stents. Importantly, 
centres performing CAS should be equipped with stents of 
different designs because the use of only one stent type 
and one protection device type (usually filter) in all treated 
patients is not a recommended strategy [3–5].
The criteria of an acceptable complication rate 
(a composite of death, stroke, and myocardial infarction) 
for interventional treatment of carotid artery stenosis 
with cut-off values of 6% in symptomatic patients and 
3% in asymptomatic patients are still valid [8, 9]. There-
fore, each new device should be compared in terms of 
safety against this accepted performance goal in centres 
with documented high volume and extensive experience 
in CAS procedures. 
Aim
The aim of this study was to evaluate the short- and 
long-term safety and efficacy of a new generation, self-ex-
panding, open-cell MER™ stent in a  group of 100 pa- 
tients who underwent internal carotid artery stenting.
Material and methods
Setting
Between October 2016 and May 2017, 100 patients 
underwent carotid artery stenting with different pro-
tection devices, with implantation of a new generation, 
self-expanding nitinol stent (MER™). The study was con-
ducted in four centres performing CAS in Poland. The Eth-
ics Committee at the Beskid Medical Chamber in Biels-
ko-Biala, Poland approved the study (opinion number: 
2015/03/26/2 dated 26.03.2015). The study was regis-
tered at ClinicalTrials.gov (NCT03133429).
Qualification and periprocedural medication
All patients provided written, informed consent. 
Prior to the procedure all patients underwent Doppler 
ultrasound examination of the carotid arteries. Some 
patients were scanned with angio-CT of the aortic arch 
and brain-supplying arteries at the operator’s discre-
tion. Symptomatic patients with ≥ 50% stenosis or as-
ymptomatic patients with ≥ 80% stenosis of ICA were 
enrolled. All patients were qualified for the procedure by 
the neurologist and underwent neurological assessment 
by the same neurologist directly after CAS, at discharge, 
and at 30 days after the procedure. All patients received 
dual antiplatelet therapy (aspirin 75 mg/day + clopido-
grel 75 mg/day) once daily for at least 3 days before the 
procedure. Post-procedural antiplatelet therapy included 
clopidogrel for 3 months and lifelong aspirin. 
Device
The MERTM carotid self-expanding stent manufac-
tured by the Balton Company is made of nitinol alloy. 
The outline of the stent is obtained by means of laser 
work. A stent is placed at the end of a  rapid-exchange 
0.014 inch delivery system. After being released from the 
delivery system, the stent opens up, taking the form of 
a cylinder. Thanks to its properties, it restores the desir-
able shape of the lumen of the vessel. The stent is placed 
between two markers at the distal end of the delivery 
system. The MER device is pictured in Figure 1.
Procedure
All hypotensive, diuretic, and anti-arrhythmic drugs 
were withheld on the day of the procedure, and all pa-
tients received 500 ml of isotonic saline before and 
during the procedure. In all patients, CAS was performed 
with the use of cerebral protection devices. 
Self-expanding open-cell nitinol MER™ carotid stents 
(Balton, Poland) were implanted in all patients.
During the procedure, patients received unfrac-
tionated heparin to maintain activated clotting time of Figure 1. The MERTM device
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250–300 s. All patients, except those with an implanted 
pacemaker, received 0.5–1.0 mg of atropine before stent 
implantation. Fifty-five patients underwent direct stent 
implantation. Post-dilation was performed in all patients 
to optimise the angiographic result of the procedure 
(residual stenosis ≤ 30%). All patients underwent pre- 
and postprocedural intracranial angiography to exclude 
periprocedural embolic complications. In most patients 
(after initial femoral artery angiography) the arterial 
puncture site was closed using a closure device. 
Follow-up
An ultrasound examination was performed before 
discharge and at 30 days, and 6 and 12 months to check 
the implanted stent. A  neurological consultation was 
done to assess any neurological incidents that occurred 
during 30-day and 1-year follow-up. 
In addition, data on the occurrence of myocardial in-
farction and death were collected. The primary endpoint 
was the 30-day and 1-year major adverse event (MAE) 
defined as cumulative incidence of death, stroke, and 
myocardial infarction.
Statistical analysis
Categorical variables are presented as numbers and 
percentages; continuous variables are expressed as 
mean ± standard deviation (SD). Differences between 
groups were compared using Student’s or Welch’s t-test 
depending on the equality of variances for normally dis-
tributed continuous variables. The Mann-Whitney U-test 
was used for non-normally distributed variables. Normal-
ity was assessed by the Shapiro-Wilk test. Equality of 
variances was assessed using Levene’s test. Categorical 
variables were compared by Pearson’s c2 test, or by Fish-
er’s exact test if 20% of cells had an expected count of 
less than five. To analyse event-free survival in selected 
risk groups, Kaplan-Meier curves were drawn. Log-rank 
statistics were used to test the differences in the out-
comes between the groups. Statistical analyses were per-
formed with JMP®, version 14.0.0 (SAS Institute Inc., Cary, 
NC, USA) and R, version 3.4.1 (R Core Team. R: A language 
and environment for statistical computing. R Foundation 
for Statistical Computing. Vienna, Austria, 2017. https://
www.r-project.org/). A p-value less than 0.05 was consid-
ered as statistically significant. This was an observational 
study, and no formal power calculations were performed 
to determine the sample size.
Results
Mean age of enrolled patients was 68.5 ±8.2 years, 
and 44 (44%) patients had a history of neurological inci-
dents during the 6 months preceding CAS (Table I).
Mean maximal carotid artery stenoses before and af-
ter the procedure were 81.98 ±9.15% and 12.52 ±8.70%, 
respectively (p < 0.001). 
Procedural details are shown in Table II. Proximal pro-
tection devices were used in 19 (19%) patients. Proce-
dural success defined as residual carotid artery stenosis 
≤ 30% was achieved in 97 (97%) patients. In 2 cases, 
additional stent implantation was needed. In all patients, 
stent implantation was followed by stent post-dilation. 
An additional stent post-dilation with a  0.5 mm larger 
balloon was performed in 2 (2%) patients due to an-
giographic criteria of plaque prolapse through the stent 
struts. Debris in the protection devices was estimated in 
one centre. Embolic material was found in 15/47 (32%) 
patients. 
Representative cases of CAS with the MER™ stent are 
shown in Figures 2 and 3. 
There was a single case of a major stroke at day four 
post procedure. No periprocedural or in-hospital myocar-
dial infarctions or deaths were observed. There were no 
cases of death, myocardial infarction, or stroke between 
discharge and day 30 (Table II, Figure 4). Doppler ultra-
sound assessment of the implanted stents confirmed 
optimal stent apposition with maintained patency of 
all stents at 1 year in surviving patients. During 1-year 
follow-up 1 patient developed in-stent restenosis that 
required a repeated procedure. The optimal clinical and 
angiographic effect was achieved in this case. There 
were 3 deaths at 1-year follow-up: 1 due to complica-
tions after myocardial infarction, 1 due to complications 
during treatment of acute leg ischaemia, and 1 due to 
suicide. Finally, Kaplan-Meier survival function showed 
97% 1-year overall survival and 99% stroke-free survival. 
Major adverse event (MAE)-free survival was 94% during 
1-year follow-up. No differences between symptomatic 
and asymptomatic patients were observed (Figure 4), 
but with 1 event in 100 patients the study was not pow-
ered for any statistical evaluation of the potential stent 
behaviour difference in symptomatic vs. asymptomatic 
carotid stenosis.
Discussion
In a cohort of 100 unselected patients qualified for 
CAS, we confirmed a good safety and efficacy profile of 
the implantation of a new MER™ CAS device. More im-
portantly, the achieved results met the established per-
formance goals for percutaneous carotid procedures. 
The number of CAS procedures is growing, and new 
stents, as well as protective devices or access modes 
(e.g. direct transcarotid access), have proven high effica-
cy in percutaneous treatment of atherosclerotic changes 
in the brain-supplying arteries [9–11]. Several years of 
experience in CAS and the growing significance of prox-
imal devices used for CAS have caused a marked reduc-
tion of the periprocedural complication rate and a shift 
from periprocedural towards postprocedural complica-
tions [12].
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Demographic and clinical characteristics:
Male gender 33 (58.9%) 28 (63.6%) 61 (61.0%) 0.63
Age [years] 68.40 ±7.83 68.32 ±8.7 68.36 ±8.20 0.73
Hypercholesterolaemia 43 (76.8%) 28 (63.6%) 71 (71.0%) 0.15
Family history of stroke 3 (5.4%) 8 (18.2%) 11 (11.0%) 0.06
Current or former smoker 27 (48.2%) 30 (68.2%) 57 (57.0%) 0.0453*
Diabetes mellitus 19 (33.9%) 20 (45.5%) 39 (39.0%) 0.24
Arterial hypertension 52 (92.9%) 39 (88.6%) 91 (91.0%) 0.50
SBP [mm Hg] 153.98 ±24.45 150.50 ±21.24 152.45 ±23.04 0.46
DBP [mm Hg] 76.77 ±10.46 80.43 ±11.88 78.38 ±11.20 0.23
Previous TIA 5 (8.9%) 14 (31.8%) 19 (19.0%) 0.0038*
Time since previous TIA: 0.0012*
< 6 months 0 (0.0%) 12 (85.7%) 12 (63.2%)  
6–12 months 0 (0.0%) 1 (7.1%) 1 (5.2%)  
≥ 12 months 5 (100.0%) 1 (7.1%) 6 (31.6%)  
Ipsilateral TIA 4 (80.0%) 12 (85.7%) 16 (84.2%) 1.00
Amaurosis fugax 0 (0.0%) 4 (28.6%) 4 (21.1%) 0.53
Previous stroke 13 (23.2%) 30 (68.2%) 43 (43.0%) < 0.0001*
Time since previous stroke: < 0.0001
< 6 months 0 (0%) 27 (90.0%) 27 (62.8%)  
6–12 months 4 (30.8%) 0 (0%) 4 (9.3%)  
≥ 12 months 9 (69.2%) 3 (10.0%) 12 (27.9%)  
Stroke type: –
Ischaemic 13 (100.0%) 30 (100.0%) 43 (100.0%)  
Haemorrhagic 0 (0.0%) 0 (0.0%) 0 (0.0%)
Ipsilateral stroke 3 (23.1%) 26 (86.7%) 29 (67.4%) 0.0001*
Hemiparesis or hemiplegia 8 (66.7%) 24 (80.0%) 32 (76.2%) 0.43
Previous MI 15 (26.8%) 10 (22.7%) 25 (25.0%) 0.64
Previous PCI 22 (39.3%) 10 (22.7%) 32 (32.0%) 0.07
Previous CABG 11 (19.6%) 2 (4.6%) 13 (13.0%) 0.0259*
Laboratory tests:
Hgb [g/dl] 13.59 ±1.29 14.32 ±1.29 13.91 ±1.33 0.0060*
Serum creatinine [mg/dl] 1.00 ±0.27 1.05 ±0.30 1.02 ±0.28 0.31
eGFR [ml/min/1.73 m²] 73.48 ±18.80 66.66 ±18.30 70.75 ±18.79 0.07
PLT [× 1000/μl] 238.46 ±59.84 256.89 ±79.94 246.57 ±69.64 0.36
RBC [× 106/mm³] 4.52 ±0.43 4.72 ±0.47 4.61 ±0.46 0.0311*
TSH [μIU/ml] 1.89 ±2.08 1.44 ±1.05 1.74 ±1.80 0.63
ALT [IU/l] 21.59 ±8.65 32.85 ±31.97 25.63 ±20.76 0.33
SBP – systolic blood pressure, DBP – diastolic blood pressure, TIA – transient ischemic attack, MI – myocardial infarction, PCI – percutaneous coronary intervention, 
CABG – coronary artery bypass grafting, Hgb – haemoglobin, eGFR – estimated glomerular filtration rate, PLT – platelets, RBC – red blood count, TSH – thyroid stim-
ulating hormone, ALT – alanine aminotransferase,  ASA – aspirin, ACEI – angiotensin convertase enzyme inhibitor. * P-value less than 0.05.
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%DS (NASCET) 77.00 ±8.75 75.38 ±10.69 76.29 ±9.63 0.30
Procedural data:
Femoral access site 56 (100.0%) 44 (100.0%) 100 (100.0%)  –
Target lesion: 0.06
CCA 5 (8.9%) 0 (0.0%) 5 (5.0%)  
ICA 51 (91.1%) 44 (100.0%) 95 (95.0%)  
Baseline %DS (angiography) 82.38 ±7.18 81.48 ±11.24 81.98 ±9.15 0.62
RVD [mm] 5.70 ±0.82 5.59 ±1.05 5.65 ±0.93 0.93
Lesion length [mm] 18.58 ±8.32 15.48 ±7.68 17.22 ±8.15 0.09
Calcification 22 (39.3%) 26 (59.1%) 48 (48.0%) 0.0491*
EPD used 56 (100.0%) 44 (100.0%) 100 (100.0%)  –
EPD device: 0.13
Emboshield 4 (7.1%) 1 (2.3%)
FilterWire 15 (26.8%) 16 (36.4%)
Mo.Ma 13 (21.2%) 6 (13.6%)
Robin 3 (5.4%) 7 (15.9%)
SpiderFX 15 (26.8%) 13 (29.6%)
WIRION 6 (10.7%) 1 (2.3%)
Proximal protection 13 (23.2%) 6 (13.6%) 19 (19.0%) 0.22
Direct stenting 26 (46.4%) 29 (65.9%) 55 (55.0%) 0.05
Postdilatation 56 (100.0%) 44 (100.0%) 100 (100.0%) –
%DS post procedure (angiography) 12.80 ±6.58 12.16 ±10.88 12.52 ±8.70 0.20
Procedural success (%DS ≤ 30%) 56 (100.0%) 41 (93.2%) 97 (97.0%) 0.08
Periprocedural complications:
Death 0 (0.0%) 0 (0.0%) 0 (0.0%) –
Periprocedural stroke 0 (0.0%) 0 (0.0%) 0 (0.0%) –
Periprocedural TIA 0 (0.0%) 0 (0.0%) 0 (0.0%) –
Periprocedural MI 0 (0.0%) 0 (0.0%) 0 (0.0%) –
Dissection 0 (0.0%) 1 (2.3%) 1 (1.0%) 0.44
Perforation 0 (0.0%) 0 (0.0%) 0 (0.0%) –
Need for 2nd stent implantation 0 (0.0%) 2 (4.6%) 2 (2.0%) 0.19
Vascular access site complications 0 (0.0%) 0 (0.0%) 0 (0.0%) –
%DS – % diameter stenosis, NASCET – North American Symptomatic Carotid Endarterectomy, CCA – common carotid artery, ICA – internal carotid artery, Fr – French, 
RVD – reference vessel diameter, EPD – embolic protection device, TIA – transient ischaemic attack, MI – myocardial infarction. * P-value less than 0.05.
It is estimated that 2/3 of all complications that oc-
cur after the CAS procedure are caused by migration of 
embolic material through the stent cells. Therefore, ade-
quate stent apposition to the atherosclerotic plaque and 
artery wall is crucial and can be best obtained with the 
use of open-cell stents. 
A second key element is to continuing dual antiplate-
let therapy for three months and acetylsalicylic acid life-
long. The size of the self-expandable MER™ stent cell is 
approximately 6.2 mm2, so it fits lover value of all open-
cell-design stents. This is a great advantage in stent de-
sign if one compares the cell area with that of the Accu-
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Figure 2. A – Symptomatic 80% right internal carotid artery stenosis. B – Protection with SpiderFX and MER™ 
stent 6–8 × 30 mm implantation followed by 5.0 × 20 mm balloon postdilatation. C – Excellent angiographic 
stent apposition with no residual stenosis
A B C
Figure 3. A  – Tight symptomatic left internal carotid artery stenosis with severe double angulation > 90°. 
The use of an 0.014 inch Grandslam support guidewire required due to the extreme angulation of the artery.  
B – Proximal protection with 8 Fr Mo.Ma – predilatation with 3.0 × 20 mm coronary balloon catheter. C – MER™ 
stent 7.0 × 20 mm implantation. D – Final optimal angiographic result
A B C D
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Figure 4. One-year Kaplan-Meier event-free survival curves for patients undergoing carotid artery stenting with 
MER™ stents. A – MAE-free survival for all patients. B – MAE-free survival for the symptomatic and asymptom-
atic patients. C – Overall survival. D – Survival for the symptomatic versus asymptomatic patients
link (Abbott) stent, at 11.48 mm2. This characteristic may 
influence the size of embolic material and therefore the 
clinical consequences caused by migration of atheroscle-
rotic plaque parts to the cerebral circulation. 
Bosiers et al. [13] demonstrated that the use of open-
cell stents is related to a higher risk of complications in 
comparison to closed-cell stents. However, our previous 
studies did not demonstrate differences in immediate and 
long-term results of CAS between both types of stents if 
cerebral protection devices and closed-cell stents were 
used in symptomatic patients and in patients with high-
risk lesions [3]. It should be noted that open-cell stents 
adapt better to tortuous segments of carotid arteries, and 
therefore they have a  well-established position as first-
choice stents in patients with tortuous and calcified ca-
rotid arteries treated with the endovascular method [14]. 
In a 2-year observation, Muller-Hulsbeck et al. found 
no difference in complications between open- and 
closed-cell stents implanted in the carotid arteries [15]. 
Recently published results of the largest meta-analysis 
presented by De Vriest et al. [16] showed no differenc-
es in 30-day and long-term complication rates between 
open- and closed-cell stents.
Today we have a  new generation of mesh stents, 
which can be used safely in high-risk lesions. First reports 
with Roadsaver and CGuard mesh stents are extreme-
ly promising due to their very low 30-day complication 
rates [6, 7, 17].
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In our study using the open-cell MER™ stent, we con-
firmed a very low complication rate of 1% during 30-day 
follow-up. It should be noted that one major stroke was 
diagnosed in a symptomatic patient shortly after an isch-
aemic incident, with new neurological symptoms at day 
four after CAS procedure, with partial aphasia that per-
sisted for over 24 h after the incident. 
MER™ stents have relatively small area cells, at 
6.2 mm2, which could also have influenced the good 
results of the procedure in the analysed group. During 
11 months of follow-up we did not observe any addition-
al strokes. Only 3 deaths were observed, including one 
due to suicide and another one due to complicated treat-
ment of leg ischaemia. 
Nowadays, it is difficult to perform CAS solely with the 
use of closed-cell stents. The properties of nitinol self-ex-
pandable stents are frequently crucial for correct conduc-
tion of a CAS procedure. However, the selection of stent 
used for CAS should be based on the morphology of the 
atherosclerotic plaque and on the anatomy of the nar-
rowed artery [3, 4, 14]. The MER™ stent could replace the 
Cristallo Ideale (Medtronic) hybrid stent, which was with-
drawn from the market several years ago. Also, the use of 
the Paladin (ContegoMedical) system with the open-cell 
carotid stent is an option in high-risk lesions [18].
The great advantage of the MER™ stent is its cross-
ing profile. All sizes of these stents are 5 Fr compatible, 
which allows the use of a 6 Fr guiding catheter or 5 Fr 
shuttle sheath. Recently, we have observed a lot of inter-
est in CAS procedures from the radial approach [19]. It 
is important that this stent can be used from the radial 
access even for the treatment of very tortuous common 
or internal carotid arteries.
The 1-year in-stent restenosis rate in our group is 
lower than the average presented in literature (1% vs. 
4.6–6.3%) [20]. The explanation for this finding may be 
the open-cell design of the stent, which provides ade-
quate stent apposition and routine post-dilatation, giving 
optimal stent expansion and lumen gain. 
A  high rate of direct stenting may be a  theoretical 
advantage. However, Lauricella et al. have recently pre-
sented data showing that target-diameter predilatation 
(without further postdiatation) may be associated with 
a significantly lower rate of macroscopic debris in protec-
tion devices [21].  
Results from this multi-centre study indicate that 
MER™ stent-supported carotid angioplasty may be a safe 
and durable procedure.
Limitations
The main limitation of the study is the fact that it 
was a one arm, non-blinded, non-randomised study, so 
a head-to-head comparison of different treatment strat-
egies was not possible. 
Moreover, no pre-procedural and post-procedural dif-
fusion-weighted magnetic resonance cerebral imaging 
[22] was performed, so we could not define the effect of 
CAS procedures in this study on post-CAS cerebral embo-
lism [23]. Finallly, visualisation in this study was limited 
to the clinically routine techniques of duplex Doppler and 
angiography, so we could not evaluate in detail the lu-
men of the artery post-procedure [24, 25].
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Figure 4. Cont. E – Freedom from stroke for all patients. F – Freedom from stroke for symptomatic and asymp-
tomatic patients
MAE – major adverse event; cumulative incidence of death, stroke, and myocardial infarction.
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Conclusions
Carotid artery stenting with nitinol open-cell MER™ 
5F stents is safe. The rate of periprocedural and 30-day 
complications is lower than the rates accepted by ESC 
guidelines. The results of 1-year follow-up are favourable 
and may support the use of this stent in the majority of 
symptomatic and asymptomatic patients scheduled for 
CAS.
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